Tepotinib (EMD-1214063) is a c-MET tyrosine kinase inhibitor (IC50=3 nM) that is selective, orally active, and ATP-competitive. Tepotinib has antitumor effect and is used in the treatment of non-small cell lung cancer.

c-Met:4 nM

Tepotinib inhibits HGF-induced c-Met phosphorylation in A549 cells with IC50 of 6 nM. Treatment with Tepotinib induces a marked reduction of c-Met–constitutive phosphorylation in EBC-1 cells with IC50 of 9 nM. Tepotinib effectively blocka phosphorylation of the major downstream effectors of the c-Met enzyme, such as Grb2, Gab1, Sos, PLCγ, and phosphoinositide 3-kinase, in EBC-1, MKN-45, and Hs746T cells in the range of 1 to 10 nM. Tepotinib considerably inhibits the viability of MKN-45 cells with IC50 of less than 1 nM. Treatment with Tepotinib (as low as 0.1 nM) inhibits HGF-induced NCI-H441 cell migration, whereas concentrations of 100 nM to 1 μM almost completely prevents it. [1]

Tepotinib treatment, at doses of 10 mg/kg or more, results in more than 90% inhibition of c-Met phosphorylation in Hs746T xenograft tumor for a period of at least 72 hours. Tepotinib induces more than 50% reduction of cyclin D1 expression, which persists after 96 hours upon treatment with doses of 100 mg/kg. A transient induction of p27 and cleaved caspase-3 are also observed upon treatment with Tepotinib. Tepotinib (15 mg/kg, daily) treatment induces complete regression of gastric carcinoma xenografts Hs746T, in which c-Met is amplified, overexpressed, and activated in a ligand-independent fashion. [1]

H2O: < 1 mg/mL (insoluble or slightly soluble)

DMSO: 5.25 mg/mL (10.66 mM), Sonication is recommended.

Ethanol: < 1 mg/mL (insoluble or slightly soluble)

5% DMSO＋95% (20% SBE-β-CD in Saline): 2 mg/mL (4.06 mM), Suspension.

0.5% CMC-Na: 2 mg/mL (4.06 mM), Suspension.

10% DMSO+90% Saline: 0.27 mg/mL (0.55 mM), Solution.